Chester County News and Community Website
WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) will present early clinical data on two cancer treatments that have advanced into Phase 3 testing at the ESMO Congress in Madrid this …
Incyte Advances Two Cancer Drugs as ESMO Congress Nears Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported that its experimental drug latarcibart reduced the median annualized bleeding rate by 81% in a 16-patient Phase 1/2 study, supporting the company’s decision …
Incyte Drug Cuts Bleeding Rate 81% in Early VWD Study Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will release its second-quarter 2026 financial results on July 28 before U.S. markets open, with executives scheduled to discuss the results during an investor …
Incyte Sets July 28 Earnings Call as Investors Await Results Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has completed its $1.25 billion acquisition of Vega Therapeutics, adding a Phase 3 treatment candidate for von Willebrand disease to its late-stage hematology pipeline …
Incyte Closes $1.25 Billion Vega Deal to Expand Hematology Pipeline Read More WILMINGTON, DE — Japan’s Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing …
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported updated early-stage clinical trial data showing its experimental antibody INCA033989 produced rapid and durable responses in patients with myelofibrosis and essential thrombocythemia, supporting …
Incyte Antibody Shows Disease-Modifying Potential in Blood Cancers Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported Phase III trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death …
Incyte Trial Data Support New First-Line Approach in Lymphoma Read More WILMINGTON, DE — Incyte has agreed to acquire Vega Therapeutics for $1.25 billion upfront in a deal that would add a late-stage treatment candidate for von Willebrand disease to the …
Incyte Agrees to $1.25 Billion Acquisition to Expand Hematology Pipeline Read More WILMINGTON, DE — Mirum Pharmaceuticals (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) are set to present pivotal Phase 2 clinical data for investigational fibrodysplasia ossificans progressiva (FOP) treatment zilurgisertib this week, …
Mirum, Incyte Advance FOP Drug as FDA Review Continues Read More WILMINGTON, DE — Incyte reported Phase 3 trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death in patients …
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival Read More